Whitepaper

Lentiviral vector programmes often accumulate risk long before preclinical development begins. Under pressure to demonstrate proof-of-concept, discovery teams make critical decisions that can unintentionally constrain manufacturability, scalability, and consistency later on. This whitepaper provides practical guidance to help you recognise and mitigate these risks early, so you can move forward with greater confidence and fewer surprises.

What you’ll learn

• Why lentiviral risk originates in discovery, not preclinical development
• The key design and process decisions that influence downstream success
• How vector architecture, promoters, and envelope choices impact scalability and consistency
• Early warning signs of manufacturability challenges
• How to balance speed and foresight without slowing your programme
• The value of early analytical and process thinking, including DOE approaches

Why it matters

Many of the challenges encountered in later-stage development can be traced back to early assumptions made during discovery. By building a clearer understanding of how early decisions affect downstream outcomes, teams can:

• Reduce costly rework
• Improve process robustness
• Accelerate progression to the clinic
• Strengthen regulatory readiness

Who should read this?

• Discovery scientists working with lentiviral vectors
• Translational and preclinical development teams
• Process development and CMC leads
• Biotech leaders advancing gene therapy programmes

👇Complete the form below to access the full case study!